This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Urologists And Henry Schein Team Up To Urge Families To Put A Prostate Cancer Check-Up On The Back To School List For Dad

Stocks in this article: HSIC

MELVILLE, N.Y., Sept. 10, 2012 /PRNewswire/ -- The Large Urology Group Practice Association, representing more than 1,800 urologists nationwide, and Henry Schein Cares, the global corporate social responsibility program of Henry Schein, Inc., are partnering together to raise awareness among families across the country of the importance of putting prostate cancer check-ups on the calendar for the men in their lives. September –  for many families, back-to-school time for the kids – is also Prostate Cancer Awareness Month. To create more public awareness about the importance of early detection of prostate cancer to save men's lives, LUGPA and Henry Schein have launched an educational initiative to put a prostate cancer check-up for Dad on the family's back to school list.

"Prostate cancer can affect any of the men in our lives – our fathers, grandfathers, husbands, brothers, uncles, sons, friends and neighbors – but with early detection this disease is almost always curable," said Dr. Deepak A. Kapoor, president of the Large Urology Group Practice Association and president of Advanced Urology Centers of New York. "As children return to school, this is a great time to remind men to have a discussion with their doctor to determine if they need a prostate check-up. Together we can help ensure that generations of men are there for not only their children's back-to-school, but for their grandkids as well."

According to Dr. Kapoor, one out of six American men will have prostate cancer in their lifetime; the incidence is even higher for African-American men and those with a family history of prostate cancer. Prostate cancer is the most common non-skin malignancy diagnosed in men; with early detection efforts, the death rate from prostate cancer has decreased by over 40% in the United States.

The largest study ever performed on screening for prostate cancer, the European Randomized Study for the Screening of Prostate Cancer (ERSPC), recently released its updated findings (N Engl J Med 2012; 366:981-990) demonstrating that for all patients there was a 21% survival advantage, and more importantly, for those with the longest follow-up (over 10 years), the advantage of screening increased to 38%. "Unfortunately, there are no symptoms during the early stages of prostate cancer, when the disease is most treatable," added Dr. Kapoor. "Despite improvement in patient education and awareness, many men still fall through the cracks; prostate cancer remains the second leading cause of cancer death in American men. The tragedy is that when the disease is caught early, the 10-year survival is almost 99% ... we all need to come together to ensure that our message is heard: early detection saves lives."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,133.25 +158.94 0.94%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,546.9470 -2.2790 -0.05%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs